Correction: SENP3 promotes tumor progression and is a novel prognostic biomarker in triple-negative breast cancer
Frontiers in Oncology · 12.05.2026 · 16
DOI: 10.3389/fonc.2026.1857283 ↗Kurz gefasst
Korrektur in der Zeitschrift Frontiers in Oncology, online erschienen am 12.05.2026. Verfasst von Youzhi Zhu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thyroid and Breast Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thyroid and Breast Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
- Department of Breast Surgery, the First Hospital of Fuzhou, Fuzhou, China.
- Key Laboratory of OptoElectronic Science and Technology for Medicine of Ministry of Education, College of Life Sciences, Fujian Normal University, Fuzhou, China.
- Central Laboratory at The Second Affiliated Hospital of Fujian Traditional Chinese Medical University, Innovation and Transformation Center, Fujian University of Traditional Chinese Medicine, Fuzhou, China.
Zitieren
APA
Zhu, Y., Zhang, J., Yu, L., Xu, S., Chen, L., Wu, K., Kong, L., Lin, W., Xue, J., Wang, Q., Lin, Y., & Chen, X. (2026). Correction: SENP3 promotes tumor progression and is a novel prognostic biomarker in triple-negative breast cancer. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1857283
Vancouver
Zhu Y, Zhang J, Yu L, Xu S, Chen L, Wu K, et al. Correction: SENP3 promotes tumor progression and is a novel prognostic biomarker in triple-negative breast cancer. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1857283
BibTeX
@article{Zhu2026,
author = {Zhu, Youzhi and Zhang, Jiasheng and Yu, Liangfei and Xu, Sunwang and Chen, Ling and Wu, Kunlin and Kong, Lingjun and Lin, Wei and Xue, Jiajie and Wang, Qingshui and Lin, Yao and Chen, Xiangjin},
title = {Correction: SENP3 promotes tumor progression and is a novel prognostic biomarker in triple-negative breast cancer},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1857283}
}
EUVIMED